Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, OH.
Hepatology. 2014 May;59(5):1750-60. doi: 10.1002/hep.26699. Epub 2014 Mar 26.
Mice deficient in small heterodimer partner (SHP) are protected from diet-induced hepatic steatosis resulting from increased fatty acid oxidation and decreased lipogenesis. The decreased lipogenesis appears to be a direct consequence of very low expression of peroxisome proliferator-activated receptor gamma 2 (PPAR-γ2), a potent lipogenic transcription factor, in the SHP(-/-) liver. The current study focused on the identification of a SHP-dependent regulatory cascade that controls PPAR-γ2 gene expression, thereby regulating hepatic fat accumulation. Illumina BeadChip array (Illumina, Inc., San Diego, CA) and real-time polymerase chain reaction were used to identify genes responsible for the linkage between SHP and PPAR-γ2 using hepatic RNAs isolated from SHP(-/-) and SHP-overexpressing mice. The initial efforts identify that hairy and enhancer of split 6 (Hes6), a novel transcriptional repressor, is an important mediator of the regulation of PPAR-γ2 transcription by SHP. The Hes6 promoter is specifically activated by the retinoic acid receptor (RAR) in response to its natural agonist ligand, all-trans retinoic acid (atRA), and is repressed by SHP. Hes6 subsequently represses hepatocyte nuclear factor 4 alpha (HNF-4α)-activated PPAR-γ2 gene expression by direct inhibition of HNF-4α transcriptional activity. Furthermore, we provide evidences that atRA treatment or adenovirus-mediated RAR-α overexpression significantly reduced hepatic fat accumulation in obese mouse models, as observed in earlier studies, and the beneficial effect is achieved by the proposed transcriptional cascade.
Our study describes a novel transcriptional regulatory cascade controlling hepatic lipid metabolism that identifies retinoic acid signaling as a new therapeutic approach to nonalcoholic fatty liver diseases.
缺乏小异二聚体伴侣 (SHP) 的小鼠可预防饮食引起的肝脂肪变性,这是由于脂肪酸氧化增加和脂肪生成减少所致。脂肪生成减少似乎是 SHP(-/-) 肝脏中过氧化物酶体增殖物激活受体γ2 (PPAR-γ2) 的表达极低的直接后果,PPAR-γ2 是一种有效的脂生成转录因子。目前的研究集中于鉴定控制 PPAR-γ2 基因表达的 SHP 依赖性调节级联,从而调节肝脂肪堆积。Illumina BeadChip 阵列(Illumina,Inc.,圣地亚哥,CA)和实时聚合酶链反应用于鉴定 SHP(-/-) 和 SHP 过表达小鼠的肝 RNA 中负责 SHP 与 PPAR-γ2 之间连接的基因。最初的努力确定了毛发和分裂增强子 6 (Hes6),一种新型转录抑制剂,是 SHP 调节 PPAR-γ2 转录的重要介质。Hes6 启动子特异性地被维甲酸受体 (RAR) 激活,以响应其天然激动剂配体全反式维甲酸 (atRA),并被 SHP 抑制。Hes6 随后通过直接抑制 HNF-4α 转录活性来抑制 HNF-4α 激活的 PPAR-γ2 基因表达。此外,我们提供了证据表明,atRA 治疗或腺病毒介导的 RAR-α 过表达可显著减少肥胖小鼠模型中的肝脂肪堆积,如早期研究中观察到的那样,并且该有益作用是通过提出的转录级联实现的。
我们的研究描述了控制肝脂质代谢的新型转录调节级联,确定了视黄酸信号作为非酒精性脂肪性肝病的新治疗方法。